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Long-term results after endovascular abdominal
aortic aneurysm repair using the Cook Zenith
endograft
Johan Mertens, MD,a Sabrina Houthoofd, MD,a Kim Daenens, MD, PhD,a Inge Fourneau, MD, PhD,a
Geert Maleux, MD, PhD,b Philip Lerut, MD,a and Andre Nevelsteen, MD, PhD,a† Leuven, Belgium
Objective: This study assessed the long-term outcome of patients with abdominal aortic and aortoiliac aneurysms treated
with the Cook Zenith endovascular graft (Cook Inc, Bloomington, Ind).
Methods: Between September 1998 and October 2003, 143 patients underwent elective endovascular aneurysm repair
(EVAR) using the Cook Zenith endograft. Data from these patients were reviewed from a prospective database in
October 2008. Primary outcome measures were overall survival, intervention-free survival, and freedom from aneurysm
rupture. Secondary outcome measures were early and late postoperative complications, including endoleaks.
Results:Mean follow-up was 66.4 months (range, 1.9-121.0 months). Overall survival was 72.1% at the 5-year follow-up
and 50.9% at the 8-year follow-up. Intervention-free survival was 77.1% at 5 years and 63.8% at 8 years. There were no
reintervention-related deaths. Six patients had a late aneurysm rupture, which was fatal in three. Freedom from aneurysm
rupture was 98.1% at 5 years and 91.0% at 8 years. Late complications occurred throughout the follow-up period, with
a tendency for aneurysm rupture and surgical conversion to occur at a later stage in the follow-up period. Aneurysm sac
enlargement during follow-up was associated with late aneurysm rupture and with the need for reintervention.
Conclusion: Elective EVAR using the Cook Zenith endograft provides excellent results through a mean follow-up of >5
years. There is a low aneurysm-related mortality and an acceptable rate of postoperative complications and reinterven-
tions. The occurrence of late complications throughout the follow-up period stresses the need for continued postoper-
ative surveillance in EVAR patients. ( J Vasc Surg 2011;54:48-57.)
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tEarly benefits of endovascular aneurysm repair (EVAR)
have been published in previous reports and demonstrated in
randomized controlled trials.1-3 Long-term outcome analysis
of patients treated with the first generations of commercially
available stent grafts has shown a considerable risk of late
complications and reinterventions.1,4-8 Device-specific early-
term to medium-term follow-up reports have shown good
results for the later generation of endografts.9-19
The Zenith endograft (Cook Inc, Bloomington, Ind) is a
third-generation device that is widely used for EVAR. It is
available in a custom-made two-part design (Fig 1, A) and in
a standard three-part design (Trifab, Fig 1, B). Long-term
surveillance of reintervention and conversion procedures after
EVAR is needed to provide evidence for the use of this
procedure as an elective option. The aim of this report is to
present our single-center results of theCookZenith endograft
after a mean follow-up of 66.4 months (range, 1.9-121.0
months).
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48ATERIAL AND METHODS
The follow-up data of 143 patients who underwent
lective EVAR were retrieved from a prospective database.
atient data were collected and recorded on case record
orms at the time of the EVAR procedure according to the
uropean Collaborators on Stent-Graft Techniques for
ortic Aneurysm Repair (EUROSTAR) criteria20,21 and as
equired by the Belgian National Health Insurance Office
RIZIV). All patients signed an informed consent form (as
equired by the RIZIV to receive reimbursement), approv-
ng with the proposed follow-up schedule and with the
nclusion of preoperative, intraoperative, and follow-up
ata in a prospective database. All EVAR procedures were
erformed between September 1998 and October 2003 at
he Gasthuisberg University Hospital in Leuven, Belgium,
nd the data were reviewed in October 2008. Inclusion and
xclusion criteria for EVAR, as defined by the RIZIV, are
ummarized in Table I (online only).
Preoperative patient risk stratification was performed
sing the American Society of Anesthesiologists (ASA)
lassification22 (Table II, online only) and the Society for
ascular Surgery (SVS)/International Society for Cardio-
ascular Surgery (ISCVS)23 risk scoring system (Table III,
nline only). As determined by risk classification derived
rom clinical assessment combined with ASA and SVS-
SCVS risk scoring, 26 patients (18.2%) were considered
nfit for open surgery.
Preoperative imaging was performed using computed
omography (CT) scans in all patients and calibrated arte-
iography in selected patients. All EVAR procedures were
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Volume 54, Number 1 Mertens et al 49performed by a member of the vascular surgery staff and an
interventional radiologist, both meeting the acknowledg-
ment criteria as defined by the Belgian National Health
Insurance Office (with theoretic and practical training, as
well as sufficient experience by having implanted a mini-
mum of 20 endografts). All procedures were performed in
the operating theater using a standard mobile image inten-
sifier. General anesthesia was used in most cases, and access
to the femoral arteries was obtained through surgical dis-
section. All patients received intravenous antibiotic prophy-
laxis with cefazolin (2 grams) and intravenous heparin
(according to body weight) during the procedure.
In the beginning of the treatment period, only the
custom-made two-part design of the Zenith endograft was
available. The first Trifab endograft was used in January
2000 and became the graft of choice.
Postoperative follow-up included plain abdominal ra-
diographs in four projections and CT scans at 3, 6, 12, 18,
and 24 months, and yearly thereafter. All plain abdominal
Fig 1. A, Cook Zenith custom-made two-part endograft. B,
Cook Zenith Trifab endograft (Courtesy Cook Medical, Inc).radiographs and CT scans were reviewed by a senior mem- 8er of the vascular surgery staff and a senior interventional
adiologist. In 16 patients, color duplex ultrasound (CDU)
maging was performed at the same intervals. In three other
atients, CT scans were performed in the beginning of the
ollow-up period and CDU was used thereafter. All CDU
rocedures were performed by a senior ultrasound techni-
ian.
Primary technical success was defined as successful de-
loyment of the endograft without type I or III endoleak,
raft limb occlusion, or conversion to open surgery. Overall
urvival, intervention-free survival, and freedom from an-
urysm rupture were analyzed as outcome parameters using
he Kaplan-Meier method. Early postoperative mortality
nd early and late postoperative complications were also
nalyzed. Late postoperative morbidity included late post-
perative complications (endoleaks, migration, graft limb-
elated complications, and stent fractures), reinterventions,
nd late conversions to open surgery. Data were analyzed
sing SPSS software (SPSS, Chicago, Ill). Continuous vari-
bles are reported as mean  standard deviation. For vari-
bles not normally distributed, as determined by a one-
ample Kolmogorov-Smirnov test, median and range are
eported. Survival analysis was performed using the Kaplan-
eier method.
ESULTS
The 143 patients (134 men and nine women) in the
tudy were a mean age of 71.3  6.9 years. The mean
reoperative serum creatinine level was 1.33 mg/dL (me-
ian, 1.21; range, 0.77-7.77 mg/dL). The mean aneurysm
iameter was 57.5 mm  10.8 mm, n  142), mean neck
ength was 26.8 mm (median, 24.0 mm; range, 7.0-85.0
m; n  122), and mean neck diameter was 24.4  3.4
m, n  130). Thirteen patients had an aneurysm neck
ength 15 mm, and 14 patients had an aneurysm neck
iameter 28 mm, which were outside of the Zenith
ndograft instructions for use.
Procedural results. A bifurcated device was used in
28 patients, of which 46 were treated with a two-part
evice, and 82 were treated with a Trifab device. An aorto-
ni-iliac device was used in 15 patients with standard
emorofemoral crossover bypass. One of the 15 aorto-uni-
liac devices implanted was used as a conversion procedure
ecause of the inability to advance the second limb of a
ifurcated device. Before the EVAR, embolization of one
nternal iliac artery was performed in 19 patients and both
nternal iliac arteries were embolized in five patients. All
dditional procedures performed concurrently with EVAR
re summarized in Table IV.
All endovascular treatments had successful procedural
utcomes without type I or III endoleaks or limb occlu-
ions, and there were no conversions to open surgery (100%
rimary technical success rate). Mean operating theater
ime (including additional procedures) was 124.7 minutes
median, 120; range, 60-360 minutes, n  142), mean
uoroscopy time was 28.1 minutes (median, 24.5; range,
-102 minutes, n  118), and the mean amount of iodine
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July 201150 Mertens et alcontrast medium used was 106.3 mL (median, 93.5; range,
35-417 mL; n  114).
Early postoperative mortality and morbidity. The
in-hospital and early postoperative (30-day) mortality rate
was 0%. Mean hospital length of stay was 4.2 days (median,
3; range 2-24 days), and mean serum creatinine level at
discharge was 1.28mg/dL (median, 1.16; range 0.71-7.35
mg/dL, n  140). Early postoperative complications oc-
curred in 19 patients (13.3%), with access site complica-
tions observed in 10 (7.0%; Table V).
Follow-up. Of the 143 EVAR patients, 141 had fol-
low-up data available until October 2008 or until the time
of death or device explantation; in four patients, imaging
data were incomplete. Mean follow-up time was 66.4 
31.3 months (range, 1.9-121.0 months).
Late mortality and morbidity. The overall survival
rate, as estimated by Kaplan-Meier analysis, was 93.6% 
2.1% at 1 year, 81.5% 3.3% at 3 years, and 72.1% 3.8%
Table IV. Additional procedures performed at the time
of the endovascular aneurysm repair (EVAR)a
Additional procedures Patients, No.
Iliac angioplasty 16 (2 bilateral)
Angioplasty for perioperative endoleak 6
● Type Ia 3
● Type Ib 1 (bilateral)
● Type III 1 (bilateral)
● Type IV 1
Fem-fem crossover graft (all AUI) 15
Preoperative embolization 26
● Internal iliac artery 24 (5 bilateral)
● Inferior mesenteric artery 1
● Lumbar artery 1
Ligation of the internal iliac artery 2
Bypass of the internal iliac artery 5
Interposition graft of the common FA 4
Embolectomy of the superficial FA 1
AUI, Aorto-uni-iliac; FA, femoral artery.
aEmbolizations were performed before the EVAR procedure.
Table V. Early postoperative complications
Complication Patients, No.
General 9
Cardiac 3
Pulmonary 1
Urinary tract infection 1
Catheter sepsis 1
Ischemic colitis 1
Thrombopenia 1
Peripheral embolizationa 1
Access site 10
Bleeding 2
Hematoma 2
Lymph leakage 5
Occlusion of the CFA 1
CFA, Common femoral artery.
aRenal insufficiency and ischemic colitis.at 5 years. The Kaplan-Meier analysis predicted the proba- (ility of survival would be about 50.9%  5.0% (n  29
emaining patients at risk) at 8 years (Fig 2). Sixty patients
42.0%) died during follow-up, and the causes of death are
ummarized in Table VI.
A late aneurysm rupture occurred in six patients (4.2%),
esulting in three deaths (2.1% aneurysm-related mortal-
ty). These six patients had aneurysm growth 5 mm
uring follow-up. An underlying endoleak was identified in
ve patients: two with known type II endoleaks, and one
ach with known type Ia endoleak (no treatment because of
echnical and comorbidity issues), a new bilateral type Ib
ndoleak, and a new type III endoleak. Reinterventions for
he ruptures are summarized in Table VII. Late aneurysm
uptures occurred after a mean follow-up of 66 months
range, 47-90 months) and five of the six late aneurysm
uptures occurred after the 5-year follow-up (Table VIII).
reedom from aneurysm rupture was 100% at 1 and 3 years.
he Kaplan-Meier estimate of freedom from aneurysm
upture was 98.1%  1.4% at 5 years and 91.0%  4.0% at
years (Fig 3).
Late postoperative complications (with or without re-
ntervention) occurred in 57 patients (39.9%), consisting of
5 patients with one event, 14 with two events, six with
hree events, and two with four events (Table VII). Late
ostoperative endoleaks occurred in 47 patients (32.9%),
ost of which were type II endoleaks without clinical
ignificance (without aneurysm sac growth) and not requir-
ng reintervention. Type I endoleak was observed in 18
atients (12.6%). Six of the type I endoleaks were type Ia
proximal fixation point in six patients) and 14 were type Ib
distal fixation point in 12 patients). Four incidences of
ype III endoleak were observed in three patients (2.8%)
ith one patient presenting with bilateral type III en-
oleaks). Three of these type III endoleaks were caused by
n iliac limb disconnection, and one had an iatrogenic cause
postcatheterization). Occurrences of type I and type III
ndoleaks throughout the follow-up period are summa-
ized in Table VIII. Migration (10mm) of the device was
bserved in one patient (0.7%), without endoleak and did
ot require reintervention.
Iliac limb stenosis (n  3) or occlusion (n  8) oc-
urred in 11 patients (7.7%). Six of eight iliac limb occlu-
ions occurred 3 months after the EVAR procedure.
tent body fractures were observed in six patients (4.2%),
nd disconnections between the main body graft and the
are metal top stent were observed in three (2.1%; Fig 4). A
ype Ia endoleak with aneurysm sac enlargement developed
n one of the three patients with a top stent disconnection.
o reintervention was performed because of technical and
omorbidity issues, and the patient subsequently died after
n aneurysm rupture. Most of the observed first-time com-
lications (59.6%) occurred during the first 2 years of
ollow-up, but they continued to occur throughout the
ollow-up period (Fig 5).
During follow-up, 48 reinterventions were performed
n 37 patients (25.9%), comprising 28 with one intervention,
ight with two interventions, and one with four interventions
Table VII). The Kaplan-Meier estimate of intervention-free
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Volume 54, Number 1 Mertens et al 51survival rate was 90.7% 2.5% at 1 year, 83.5% 3.2% at 3
years, and 77.1%  3.8% at 5 years. The Kaplan-Meier
analysis predicted the probability of intervention-free sur-
vival would be about 64.8%  5.8% (n  19 remaining
patients at risk) at 8 years (Fig 6). During the first 2 years of
follow-up, 48.6% of the first-time reinterventions were
performed, and reinterventions continued to be performed
throughout the follow-up period (Fig 5). There were no
deaths related to reintervention, although one patient died
of cardiac causes 2 months after thrombolysis of an oc-
cluded iliac limb (complicated with bleeding).
Late conversion to open surgery was performed in five
patients (3.5%), and indications for endograft removal were
type Ia endoleak in two patients, and one patient each with
persisting type II endoleak with aneurysm sac enlargement
despite embolization, type III endoleak with aneurysm
rupture (urgent reintervention and conversion), and endo-
tension with aneurysm sac enlargement. Late conversions
to open surgery occurred after a mean of 54months (range,
Fig 2. Cumulative survival ana
Table VI. All causes of late postoperative mortality
Causes Patients, No. (N  60)
Late aneurysm rupture 3
Cardiac 16
Cerebrovascular 7
Malignancy 17
Pulmonary 5
Other 1232-65 months), and three of the five conversions occurred ifter 5 years (Table VIII). During further follow-up, all
atients who underwent conversion had a favorable out-
ome without aneurysm-related complications or further
einterventions.
Mean aneurysm sac diameter was 54.2 11.3mm (n
16) at 1 year, 49.2  15.7 mm (n  98) at 3 years, and
6.2  15.6 mm (n  60) at 5 years. Aneurysm sac
hrinkage (5 mm) was observed in 89 of 143 patients
62.2%). In 59 patients, aneurysm sac shrinkage was ob-
erved at 1 year (in three of these patients, there was
neurysm sac growth at a later stage during follow-up), in
7 patients sac shrinkage was observed at 3 years, and in
nother three patients at 5 years. Significant increase (5
m) in aneurysm sac diameter was observed in 25 of the
43 patients (17.5%). Aneurysm sac growth was observed
t 1 year in 18 patients, at 3 years in five patients, and at 5
ears in another two patients. In 10 of 18 patients with
neurysm growth at 1 year, an endoleak was observed (two
ype Ia, two type Ib, and six type II). In five of seven
atients with aneurysm growth at the 3- or 5-year follow-
p, an endoleak was observed (one type Ib, three type II,
nd one type III). In three of these seven patients, aneu-
ysm sac shrinkage (5 mm) was observed at an earlier stage
uring follow-up, including one patient with a type III en-
oleak andonepatientwith a type II endoleak thatwas treated
y embolization, but later this patient developed a type Ia
ndoleak with subsequent rupture of the aneurysm.
A reintervention was performed in 17 of 25 patients
68.0%) with significant aneurysm growth during follow-up.
ll late aneurysm ruptures also occurred in patients with an
N, Number of patients at risk.ncrease in aneurysm sac diameter of 5 mm. No significant
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July 201152 Mertens et aldifferences were noted in mean preoperative aneurysm diam-
eter, neck length, or neck diameter between patient groups
with andwithout significant aneurysm sac enlargement (Table
IX).
In the 13 patients with a preoperative aneurysm neck
length 15 mm, two postoperative stent fractures occurred
during follow-up, but therewas no need for reintervention. In
the 14 patients with a preoperative aneurysm neck diameter
28 mm, four late postoperative complications occurred,
comprising two iliac limb stenoses, one type Ib endoleak, and
one type II endoleak, with one reintervention stenting for
limb stenosis and one extension for a type Ib endoleak.
DISCUSSION
This report presents the long-term follow-up results
Table VII. Late postoperative complications and reinterve
Complications Patients, No.
Late aneurysm rupture 6
Endoleak 47
Type Ia 6
Type Ib 12 (1 bilateral, 1 of these w/r
Type II 25 (33 endoleaks; 6 were pers
embolization)
Type III 3 (1 bilateral, 1 iatrogenic)
Endotension 1
Limb stenosis or occlusion 11
Stent body fracture 6
Disconnection of top stent device
migration
3 (1 leading to a type Ia endo
subsequent rupture); 1 (wit
Aneurysm outside of the device 6
Complication related to fem-fem
crossover bypass
4 (1 stenosis, 2 occlusions, 1
Table VIII. Occurrences of type I and type II endoleaks,
throughout the follow-up period
Event/reintervention 6 mo 6 mo-1 yr
Type Ia endoleak 1 1
Type Ib endoleak 1 2
Type III endoleak
Late aneurysm rupture
Late conversion to open surgery(mean follow-up of 66.4 months) of our single-center 0xperience with the use of the Cook Zenith endograft for
he elective treatment of abdominal aortic and aortoiliac
neurysms. In other published reports of the Zenith
ndograft, mean follow-up ranged from 7 to 26.9
onths.13-15,19 Greenberg et al17 reported the 5-year
esults of the Zenith U.S. multicenter trial in 2008, and
he UK EVAR trial investigators have recently published
heir long-term results of the EVAR 1 and 2 trials, which
ncluded patients treated with the Zenith and other
ndografts.24,25
In this series, the primary technical success rate was
00%, and there was no early postoperative mortality. In
reviously published reports of the Zenith endograft, the
rimary technical success rate ranged from 91% to 100%,
nd early postoperative (30-day) mortality ranged from
ns
Reinterventions
3 died
1 conversion
1 distal endograft extension
1 drainage of the aneurysm sac
2 untreated
2 conversions
2 proximal extensions
re) 5 untreated
8 distal endograft extensions (1 bilateral)
t after 21 untreated
11 embolizations (9 patients)
1 conversion (sac enlargement despite
embolization)
1 conversion
2 distal endograft extensions
1 endovascular occlusion  crossover bypass
1 conversion
2 untreated
5 endovascular treatments
4 crossover bypasses
endoleak)
Not requiring reintervention
4 distal endograft extensions (1 bilateral)
1 covered stent of internal iliac artery aneurysm
1 aortic tube interposition
ion) 1 untreated
1 endovascular treatment
2 redo crossover bypasses
neurysm ruptures, and late conversions to open surgery
1-3 yrs 3-5 yrs 5 yrs Total events, No.
1 3 6
3 1 7 14 (12 patients)
1 (iatrogenic) 2 1 4 (3 patients)
1 5 6
2 3 5ntio
uptu
isten
leak,
hout
infectlate a.1% to 4.1%.13-19
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Fig 3. Freedom from aneurysm ruptur
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Volume 54, Number 1 Mertens et al 53Mean overall survival in this study was 72.1% at 5 years
nd 50.9% at 8 years. The intervention-free survival was 77.1%
t 5 years and 64.8% at 8 years. During the follow-up period,
ve devices (3.5%) were explanted and 48 reinterventions
ere performed in 37 of the 143 patients (25.9%). When
omparedwith recently publishedmedium-term to long-term
esults with theZenith endograft, the survival rates are similar;
owever, a higher rate of late aneurysm ruptures, conversions
o open surgery, and reinterventions in general was observed
n this series.13-19 Possible contributing factors are the inten-
ity of the follow-up program, the availability of nearly all
atient data for follow-up, and the longer follow-up period.
This retrospective analysis is not a clinical trial, and the
election of patients for EVAR reflects the clinical practice
t the time of the treatment period (1998-2003). This
reates a possible selection bias, because at that time there
as a tendency to perform EVAR in higher-risk patients
ho have been shown to have a higher risk of aneurysm-
elated morbidity during follow-up.3,17 In a report based
n the U.S. multicenter Zenith trial,17 Greenberg et al
emonstrated a 5-year intervention-free survival of 80.5%
n a standard-risk patient group and 75.2% in a high-risk
atient group, the latter being comparable to the 5-year
ntervention-free survival in our patient series. In the UK
VAR 1 trial patient group (51% of patients treated with
he Zenith endograft), there was a 54% overall survival and
93% aneurysm-related survival at the 8-year follow-up,
hich is similar to the results in this patient series.24 For the
VAR 2 patient group (60% of patients treated with the
enith endograft), overall survival at 8 years was 30% and
e. N, Number of patients at risk.Fig 4. Plain abdominal radiograph shows a disconnection of the
neurysm-related survival was 86%.25
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July 201154 Mertens et alMost late complications and reinterventions in this patient
series were observed during the first year(s) of follow-up, but
throughout the follow-up period, a risk remained for patients
to develop a first-time event with or without reintervention
(Fig 5). Reinterventions can often be performed by endovas-
cular means with few complications. No deaths in this patient
series were related to reintervention. The most serious late
postoperative events and reinterventions showed a tendency
Fig 5. Occurrence of first-time complications and first-t
ing number of patients at risk at the beginning of each f
Fig 6. Cumulative analysis of interventioto occur or be performed later in the follow-up period, with aate aneurysm ruptures and conversions to open surgery oc-
urring or being performed after a mean follow-up of 66 and
4 months, respectively. Fifty percent of type I endoleaks
ccurred after 5 years, and all but one (iatrogenic) type III
ndoleaks occurred after 3 years. These findings stress the
eed for continued postoperative surveillance of EVAR pa-
ients.
Concerns related to the use of iodinated contrast
interventions throughout the follow-up period (includ-
-up year).
e survival. N, Number of patients at risk.ime regents, cumulative radiation exposure, and the costs of CT
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Volume 54, Number 1 Mertens et al 55imaging have raised interest in the development of new
EVAR surveillance regimens. In a recently published report
based on the U.S. multicenter Zenith trial26 and in the
recently published SVS practice guidelines for the care of
patients with an AAA,27 contrast-enhanced CT imaging is
recommended at the 1- and 12-month follow-up visit after
EVAR, and CT imaging at 6 months is performed only if
the 1-month examination raises concerns. If neither an
endoleak nor aneurysm enlargement is documented during
the first year after EVAR, CDU may be a reasonable alter-
native for CT imaging in postoperative surveillance.26,27
The role of CDU in surveillance of EVAR patients has also
been described in other published reports.28-30
Aneurysm sac shrinkage (5 mm) was noted in 62.2%
of patients. A significant increase in aneurysm sac diameter
(5 mm) was seen in 25 patients (17.5%) and was associ-
ated with the risk of aneurysm rupture and the need for
reintervention. There was no significant difference in pre-
operative aneurysm diameter, neck diameter, or neck
length when patients with expanding sac size were com-
pared with the rest of the patients in this series. Other
published reports, however, have described predictive fac-
tors of postoperative aneurysm sac enlargement and en-
doleak occurrence, including preprocedure aneurysm di-
ameter, neck thrombus, plaque or calcification, neck
angulation, and patient gender.31-33
Patients in this series with short aneurysm necks or
large-diameter necks outside of the Zenith’s instructions
for use did not seem to have more complications or rein-
terventions.
Suprarenal fixation with a bare metal top stent is one of
the device-specific characteristics of the Zenith endograft.
As a result, the incidence of device migration is very low in
all previously published results of the graft.12-19 In this
series, migration was observed in one patient (0.7%), in
which the migration remained unchanged during further
follow-up and did not require reintervention.
The interrupted stent design of the Zenith device is
thought to be associated with a higher risk of iliac limb
kinking, stenosis, or occlusion.14,16,17,19,34,35 Iliac limb
Table IX. Baseline preoperative measurements in
patients with observed aneurysm sac growth of 5 mm
compared with patients without sac growth
Aneurysm sac
Preoperative
measurements
growth
5 mm No sac growth P1 P2
Aneurysm diameter,
mean mm
57.3  9.2 57.1  10.4 .91 .99
Neck length, mean
mm
24.9  8.7 27.0 .37 .98
Median (range),
mm
23 (7-85)
Neck diameter, mean
mm
23.7  3.1 24.6  3.6 .24 .33
P1, Independent samples t test; P2, nonparametric Mann-Whitney test.stenosis occurred in three patients (2.1%) in this series and ecclusion in eight (5.6%). Most iliac limb occlusions oc-
urred shortly after the EVAR procedure, which has been
eported previously.35 Most of these complications related
o the graft limb occurred in patients treated with the earlier
eneration of the device during the first 2 years of the
reatment period. In the later stages, these iliac graft limb-
elated complications were prevented by more careful pa-
ient selection and the preferable use of other endografts in
he treatment of patients with tortuous or narrow iliac
rteries.
More recently, the manufacturer has also made changes
n the device and stent design of the iliac limbs (increased
pacing between Z-stents) to increase the compatibility
ith difficult iliac anatomy. Iliac limb disconnection (with
ype III endoleak) was seen in two patients (1.4%, one
ilateral case). One patient had a two-part endograft and
he other patient (bilateral case) had a Trifab endograft.
heoretically, there is a greater risk of limb disconnection
n the standard Trifab three-part design compared with the
ustom-made two-part design.14,19
Fractures in the metallic stent design were observed in
ix patients (4.2%) during follow-up. In five patients, these
ractures occurred in the most distal stent proximal to the
evice’s bifurcation, and there is possible concern that these
ractures are associated with the occurrence of type III
ndoleaks. However, this has not been published in previ-
us reports of the Zenith endograft,16,17,24 nor was it
bserved in this patient series. The manufacturer altered
he endograft design in 1999, shortening the most distal
ody stent from 22 to 14 mm. In this patient series, four of
ve patients with a fracture of themost distal body stent had
een implanted with grafts before the change in device
esign. The identification of stent fractures requires thor-
ugh review of follow-up examinations because minor
tent graft changes are not always easily identified and are
ometimes missed by the reviewer or the radiologist.
In another three patients (2.1%), a disconnection of the
are metal top stent from the endograft main body (Fig 4)
as observed. In one of these patients, a type Ia endoleak
eveloped with subsequent aneurysm rupture. This com-
lication has previously been reported in older Zenith
ndografts16,17,19 and in the meantime, the manufacturer
as altered the graft design, providing a more secure fixa-
ion of the bare top stent to the body of the endograft. The
ast reported top stent disconnection in our series occurred
n an endograft placed in May 2001.
ONCLUSION
The Cook Zenith endograft is a safe and durable device
or the elective endovascular treatment of abdominal aortic
nd aortoiliac aneurysms. This patient series provides good
esults through a mean follow-up period of 5 years, with
low aneurysm-related mortality and an acceptable reinter-
ention rate. Results have also improved because of in-
reased experience with the graft, better patient selection,
nd improved stent graft design. Late complications oc-
urred throughout the follow-up period, whereas late an-
urysm rupture and conversion to open surgery showed a
11
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
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July 201156 Mertens et altendency to occur or be performed later in the follow-up
period, stressing the need for continued follow-up in pa-
tients treated with the Zenith or any other endograft.
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Volume 54, Number 1 Mertens et al 57.e1Table I (online only). Inclusion and exclusion criteria for
the Belgian National Health Insurance Office (RIZIV)
Inclusion criteria
Aneurysm size
Fusiform aneurysm 5 cm
Fusiform aneurysm 4-5 cm if:
● 2 diameter of the native aorta
● 5 mm growth in 6 months
● Symptomatic patient with back or abdominal pain
● Aneurysm tender on palpation
● Patient 65 years
● Family history of aneurysm (first degree)
● Fusiform iliac aneurysm 2 cm
Saccular aneurysm of any size
Anatomic criteria
Minimal proximal neck length of 1 cm, 10%-20% smaller than
available device
Minimal distal landing area of 1 cm, 10%-20% smaller than
available device
Iliofemoral and/or brachial access suitable for available devicethe endovascular treatment of aortic aneurysms as defined by
Exclusion criteria
General criteria
2 year life expectancy
Mycotic aneurysm or infectious arteritis
Active remote infection
Hemophilia or known bleeding diathesis
Marfan syndrome and other genetic connective tissue
diseases
Anatomic criteria
70° proximal neck angulation and/or heavily calcified
proximal neck (circular calcifications)
Thrombus 3 mm or 1/3 of the circumference at the
level of the proximal neck
Iliac tortuousities and calcifications preventing deployment
of the introducer sheath
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July 201157.e2 Mertens et alTable II (online only). Preoperative patient risk
stratification using the American Society of
Anesthesiologists (ASA) physical status classification
ASA classification Patients, No.
1 11
2 85
3 45
4 2
Class 1—Healthy patient for elective operation.
Class 2—Patient with mild systemic disease, limits activity but is not inca-
pacitating.
Class 3—Patient with severe systemic disease that is a constant threat of life,
limits activity, but is not incapacitating.
Class 4—Patient with incapacitating systemic disease that is a constant threat
of life.
Class 5—Moribund patient, not expected to live 24 hours without opera-
tion.
D
i
S
i
H
w
H
e
d
C
a
o
a
a
c
C
a
s
R
c
c
t
d
P
f
o
p
v
l
oable III (online only). Preoperative patient risk
tratification using the Society for Vascular Surgery
SVS)/International Society for Cardiovascular Surgery
ISCVS) risk scoring system
SVS-ISCVS
risk scoring
Available
data
ariable 0 1 2 3 (n  143)
iabetes 130 6 7 0 143
moking 62 46 29 6 143
ypertension 59 49 26 9 143
yperlipidemia 67 34 5 35 141
ardiac status 57 48 27 11 143
arotid status 115 25 2 0 142
enal status 117 24 1 1 143
ulmonary status 81 37 18 6 142
iabetes: 0  none; 1  adult onset, diet controlled; 2  adult-onset,
nsulin-controlled; 3  juvenile onset.
moking: 0 none or none for last 10 years; 1 none current, but smoked
n last 10 years; 2  current, 1 pack/day; 3  current, 1 pack/day.
ypertension: 0  none; 1  easily controlled with 1 drug; 2  controlled
ith 2 drugs; 3  requires 3 drugs or uncontrolled.
yperlipemia: 0  cholesterol/triglycerides normal for age; 1  mild
levation, controllable by diet; 2  types II, III, or IV, requiring strict
ietary control; 3  requiring dietary and drug control.
ardiac status: 0  asymptomatic, normal electrocardiogram (ECG); 1 
symptomatic, remote myocardial infarction (MI) history (6 months) or
ccult MI by ECG; 2  stable angina, controlled ectopia or symptomatic
rrhythmia, drug-compensated congestive heart failure (CHF); 3 unstable
ngina, symptomatic or poorly controlled ectopy or arrhythmia, poorly
ompensated CHF, MI 6 months.
arotid disease: 0  no symptoms, no bruit, no evidence of disease; 1 
symptomatic, but with evidence of disease; 2  transient or temporary
troke; 3  completed stroke with permanent neurologic deficit.
enal status: 0  no known renal disease, serum creatinine 1.5 mg/dL,
reatinine clearance 50 mL/min; 1  creatinine 1.5 to 3.0 mg/dL,
learance 30 to 50 mL/min; 2 creatinine 3.0 to 6.0 mg/dL, clearance 15
o 30 mL/min; 3 creatinine6.0 mg/dL, clearance15 mL/min or on
ialysis or with transplant.
ulmonary status: 0  asymptomatic, normal chest radiograph, pulmonary
unction tests (PFT) 80% of predicted; 1  asymptomatic or mild dyspnea
n exertion, mild radiograph parenchymal changes, PFT 65% to 80% of
redicted; 2 between 1 and 3; 3 vital capacity1.85l, forced expiratory
olume in 1 second 1.2l or 35% of predicted, maximal voluntary venti-
CO 45 mmHg, supplementalation28 L/min or50% of predicted, P 2
xygen use necessary or pulmonary hypertension.
